We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Igor Puzanov

Igor Puzanov MD, MSCI, FACP

Professor of Medicine; Director, Early Phase Clinical Trials Program; Co-Leader, Developmental Therapeutics Program; Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Dr. Puzanov is an assistant professor of medicine in the Department of Hematology/Oncology, Vanderbilt University School of Medicine, and associate director of the Phase I Drug Development Program, Vanderbilt University, Nashville, Tennessee. In addition, Dr. Puzanov holds the position of associate professor of oncology at the Masaryk University Faculty of Medicine, Brno, Czech Republic.

Since finishing his medical training at the Charles University, Prague, Czech Republic, Dr. Puzanov has participated in the immunology graduate program at the University of Texas at Dallas and completed his master of science in clinical investigation at Vanderbilt University. He is a member of many professional organizations, including the Melanoma Research Foundation Breakthrough Consortium, Melanoma Committee of the Eastern Cooperative Oncology Group (ECOG), Cytokine Working Group, American Society of Clinical Oncology, and American Association for Cancer Research. Dr. Puzanov’s research interests lie in translational research and personalized drug development for the treatment of melanoma and renal cell carcinoma, as well as the cardiovascular and dermatologic toxicities of targeted agents. He has been involved in the development and execution of multiple clinical trials for the treatment of patients with metastatic melanoma.